RxDoctor Payments Data

Andrew Pugely, MD

Orthopaedic Surgery of the Spine · Iowa City, IANPI 1508185521

Payments from drug & device makers

What this record shows

The money is spread across several categories — royalties or licence payments (47.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Globus Medical accounts for 68.3% of it on its own, with 7 other manufacturers making up the rest.

$208,214in general payments, 2019–2025

Across 308 payments — averaging $676.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Globus Medical$142K
  • Medtronic$53K
  • Mirus, LLC$10K
  • Smaio SA$3K
  • Stryker$244
  • Bioventus LLC$118
  • plus $44 from 2 others
$174,500in research payments, 2019–2025

Across 2 payments — averaging $87,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$140K
  • Globus Medical$35K

What the payments were for

  • Royalty or licence$97,92047%
  • Consulting fees$57,11927%
  • Speaking & faculty fees$17,7889%
  • Travel & lodging$27,05713%
  • Food & beverage$8,3304%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Globus Medical(2 entities)88$142,282
Medtronic(2 entities)194$53,050
Mirus, LLC13$9,587
Smaio SA5$2,888
Stryker5$244
Bioventus LLC1$118
Covis Pharma GmbH1$28
Johnson & Johnson1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few orthopaedic surgery of the spine providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$469,835
Medicare patients
310
Services billed
1,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib39$1,420
Gabapentin24$192
Baclofen18$136
Cyclobenzaprine Hcl12$68
Tramadol Hcl12$42

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery of the spine in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →